Basic Information
| LncRNA/CircRNA Name | circPLK1 |
| Synonyms | |
| Region | |
| Ensemble | |
| Refseq |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | NA | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | triple negative breast cancer |
| ICD-0-3 | C50 |
| Methods | qRT-PCR , CCK-8 assay , transwell assay , Western blotting , luciferase reporter assay , RIP |
| Sample | TNBC tissues and paired adjacent normal mammary tissues ,normal mammary epithelial cell lines MCF10A, and breast cancer cell lines (MDAMB-468,MDA-MB-453, MDA-MB-231, HCC38 and BT549) |
| Expression Pattern | up-regulated |
| Function Description | CircPLK1 was significantly upregulated in TNBC and associated with poor survivals. CircPLK1 knockdown inhibited cell growth and invasion in vitro as well as tumor occurrence and metastasis in vivo. CircPLK1-miR-296-5p-PLK1 axis regulates tumor progression by ceRNA mechanism in TNBC, indicating that circPLK1 may serve as a prognostic factor and novel therapeutic target for TNBC. |
| Pubmed ID | 31337246 |
| Year | 2019 |
| Title | CircPLK1 Sponges miR-296-5p to Facilitate Triple-Negative Breast Cancer Progression |
External Links
| Links for circPLK1 | GenBank HGNC NONCODE |
| Links for triple negative breast cancer | OMIM COSMIC |